Consistently, a recent study using a panel of cancer cell lines found that treatments with the TEAD inhibitor MGH-CP1 and YAP/TAZ silencing both promoted the VGLL3-mediated transcriptional activation of SOX4/PI3K/AKT signaling, which contributed to resistance to MGH-CP1 [83]. Here, AKT1 is linked to cancer.